Navigation Links
Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
Date:6/15/2009

SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), a leader in the development of a new class of small molecule compounds based on endogenous adrenal steroid hormones, today announced the board of directors has appointed James M. Frincke Ph.D. as President and CEO of Hollis-Eden Pharmaceuticals, Inc. Dr. Frincke was also elected to the company's board of directors.

Dr. Frincke joined Hollis-Eden as Vice President, Research and Development in 1997, was promoted to Executive Vice President in 1999, and to Chief Scientific Officer in 2001. Dr. Frincke joined Hollis-Eden from Prolinx, Inc., where he served as Vice President, Therapeutics Research and Development from 1995 to 1997. During his 28 years in the biotechnology industry, Dr. Frincke has managed major development programs including drugs, biologicals, and cellular and gene therapy products aimed at the treatment of cancer, infectious diseases and organ transplantation. Since joining the biotechnology industry, Dr. Frincke has held vice president, research and development positions in top tier biotechnology companies including Hybritech/Eli Lilly and SyStemix Inc. (acquired by Novartis). In various capacities, he has been responsible for all aspects of pharmaceutical development including early stage research programs, product evaluation, pharmacology, manufacturing, and the management of regulatory and clinical matters for lead product opportunities. Dr. Frincke has authored or co-authored more than 100 scientific articles, abstracts and regulatory filings. Dr. Frincke received his B.S. in Chemistry and his Ph.D. in Chemistry from the University of California, Davis. Dr. Frincke completed his postdoctoral work at the University of California, San Diego. Dr. Frincke has been with Hollis-Eden for more than 11 years.


'/>"/>
SOURCE Hollis-Eden Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)
2. Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients
3. Jubilant to Work With Endo Pharmaceuticals on Drug Development
4. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
5. ADVENTRX Pharmaceuticals Announces Financing
6. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
7. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
8. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
9. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
10. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
11. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 ... using the company,s  proprietary AMCA Guided Bone Regeneration (GBR) Dental ... implants. A common problem encountered when patients have ... of sufficient bone volume to house the implant. Consequently there ... bone substitute until the natural bone regenerates. The bone substitute ...
(Date:6/18/2013)... information — Global biopharmaceutical company UCB, Inc. and professional ... of a new Pledge campaign for people with epilepsy ... empowers the millions of Americans living with epilepsy ... to demand more: greater understanding of the condition, better ... seizure control.  More information is available at www.ourtimeourpledge.com ...
(Date:6/18/2013)... , June 18, 2013  AMRI (NASDAQ: ... Burlington, Mass. , site has received ... Administration (DEA) registration to handle Schedule 2 and ... acknowledgement of Burlington,s physical ... documentation. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) ...
(Date:6/18/2013)... Israel , June 18, 2013 ... Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished ... that the company has been granted a United ... the US and Europe for the ... number 8,410,176 B2 is titled Intermediate Compounds and Processes ...
Breaking Biology Technology:RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2
... , THE WOODLANDS, Texas , June 3 ... company focused on discovering and developing breakthrough treatments for human disease, ... vice president of pharmaceutical research, will present at two investor conferences ... at the 9th Annual Needham Healthcare Conference on Wednesday, June ...
... Calif. , June 3 Anthera Pharmaceuticals, Inc. (Nasdaq: ... with inflammation and autoimmune disorders, today announced Colin Hislop , M.D. ... Dr. Hislop replaces James E. Pennington , M.D., who will continue ... , , ...
... OriGene Technologies, Inc., a leading gene-centric life sciences company, has announced ... labeled human proteins as internal standards for SRM/MRM (single reaction monitoring, ... at the 2010 American Society for Mass Spectrometry conference in ... , , ...
Cached Biology Technology:Lexicon to Present at Two Major Healthcare Investor Conferences 2Lexicon to Present at Two Major Healthcare Investor Conferences 3Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer 2Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer 3Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer 4OriGene Technologies Launches Over 5,000 Heavy Isotope Labeled Full-Length Human Proteins as Quantitative Internal Standards for SRM/MRM Mass Spectrometry 2
(Date:6/18/2013)... A UT Arlington environmental engineer has been awarded ... District to ensure water quality and flow in ... Project. , Andrew Kruzic, UT Arlington associate professor ... and locations to add monochloramine to the water ... the new pump stations and pipelines. Adding monochloramine ...
(Date:6/18/2013)... $12.7 million to match nine academic research groups ... explore new treatments for patients in eight disease ... schizophrenia. The collaborative pilot initiative, called Discovering New ... the National Center for Advancing Translational Sciences (NCATS) ... The process of developing a new therapeutic is ...
(Date:6/18/2013)... and 10% of breast and ovarian cancers are familial ... are attributable to inherited mutations from the parents in ... these mutations, PARP inhibitors, which are currently in clinical ... new option for personalised cancer treatment, an alternative to ... fraction of these patients generate resistance to the drug ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
... looked carefully at the leaves on a plant and noticed ... controls the size and shape of each individual leaf? Very ... and shape, and understanding the mechanisms behind this is a ... size is determined by a combination of cell number, cell ...
... professor of biomedical engineering at NJIT, has received a patent ... is a derivative of isosorbide and may be able to ... including the lining of tin cans. Jaffe has ... Promotion Board (ICPB) in an effort to promote and create ...
... A University of Iowa study supports an earlier UI ... Indiana Harbor and Ship Canal (IHSC) in East Chicago, Ind. ... a significant source of PCBs found in surrounding air and ... edition of the journal Environmental Science and Technology ...
Cached Biology News:Can a single layer of cells control a leaf's size? 2Can a single layer of cells control a leaf's size? 3NJIT patent may be able to replace BPA, make consumer products safer 2UI study measures levels of PCBs flowing from Indiana canal to air and water 2
Blue Standard is 3-cyano-7-hydroxycoumarin....
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...
Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1). [Source:Uniprot/SWISSPROT;Acc:P42892] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: